Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nureca's Dr Trust 360 connected health platform has reached over 2.4 million registered users, reflecting growing adoption of home healthcare. The company also launched Dr Trust Intelligence, an AI-powered analytics suite providing personalized health insights.
Jun 20 2026 14:55:11
Nureca Ltd - 543264 - Disclosure Under Regulation 30 And Regulation 30A Read With Clauses 5 And5a Of Para A Of Part A Of Schedule III Of Securities And Exchange Board Of India
('SEBI') (Listing Obligations And Disclosure Requirements) Regulations, 2015
('LODR Regulation')
Nureca announced CEO Aryan Goyal's resignation and director departure. This follows a family settlement agreement where promoter shares, including those of Aryan and Payal Goyal, will be transferred to Chairman & MD Saurabh Goyal, consolidating his holding to 68.09%.
Jun 20 2026 11:35:50
Nureca Ltd - 543264 - Nureca Limited Has Informed The Exchange Regarding No Change In The Aggregate Shareholding Of The Promoter And Promoter Group Of The Company Pursuant To Inter Se Transfer Of Shares.
Nureca disclosed an inter se transfer of 60,842 equity shares from Nectar Biopharma Private Limited to Mr. Saurabh Goyal, both part of the promoter group. This internal reallocation does not alter the total shareholding of the promoter and promoter group in the company.
Jun 10 2026 01:13:06
Nureca Ltd - 543264 - Nureca Limited Has Informed The Exchange Regarding Disclosure Under Regulation 7(2) Of SEBI (PIT) Regulations ,2015
Nureca's promoter group, Nectar Biopharma Private Limited, disposed of its entire 0.63% shareholding, totaling 60,842 equity shares, through an off-market transaction. The sale, valued at Rs.1.43 crore, resulted in the promoter group's holding becoming NIL.
Jun 10 2026 00:43:08
Nureca Ltd - 543264 - Nureca Limited Has Informed The Exchange Regarding Corrigendum Pursuant To The Outcome Of The Board Meeting Submitted On 29Th May,2026.
Nureca announced a corrigendum, increasing the approved incremental CAPEX from Rs. 100 crores to Rs. 128 crores. This investment is for expanding manufacturing of medical devices, healthcare consumables, and hygiene products, along with purchasing additional land at Sundran, Derabassi, Punjab.
Jun 01 2026 18:35:24
Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Change in Management
Nureca has appointed Chander Kant as its new Chief Financial Officer (CFO), effective June 27, 2026. This appointment follows the resignation of Mr. Naresh Gupta, effective June 26, 2026. Mr. Kant was previously the company's Manager Finance.
May 30 2026 14:46:11
Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Change in Management
Nureca announced the appointment of Mr. Chander Kant as its new Chief Financial Officer (CFO), effective June 27, 2026. This follows the resignation of Mr. Naresh Gupta, effective June 26, 2026. The board also approved the re-appointment of Mr. Aryan Goyal as WTD & CEO and Mr. Saurabh Goyal as MD for three years.
May 29 2026 20:45:00
Nureca Ltd - 543264 - Announcement under Regulation 30 (LODR)-Change in Management
Nureca announced the appointment of Mr. Chander Kant as its new Chief Financial Officer (CFO), effective June 27, 2026. This follows the resignation of Mr. Naresh Gupta, effective June 26, 2026. The board also approved the re-appointment of Mr. Aryan Goyal as WTD & CEO and Mr. Saurabh Goyal as MD for three years.
May 29 2026 20:31:37
Nureca Ltd - 543264 - Board Meeting Outcome for Nureca Limited Has Informed The Outcome Of Board Meeting
Nureca's board approved Q4 FY26 and full year FY26 consolidated financial results, with full year revenue at ₹146.96 cr (up 34% YoY) and net profit at ₹2.08 cr (up 147% YoY). The company also approved a ₹100 cr capex for plant expansion and land acquisition in Punjab, appointed Mr. Chander Kant as CFO, and re-appointed Mr. Aryan Goyal as WTD & CEO and Mr. Saurabh Goyal as MD.
May 29 2026 19:05:06
Nureca Ltd - 543264 - Nureca Limited Has Informed The Exchange Regarding : Intimation Under Regulation 30 Of The Securities And Exchange Board Of India(Listing Obligations And Disclosure Requirements) Regulations, 2015
Nureca received a hearing notice from the Directorate of Revenue Intelligence (DRI) regarding product classification. The company made a pre-deposit of Rs.57.12 lakh. This payment does not admit liability but addresses an ongoing regulatory matter.
May 24 2026 09:26:14
Read More